Organic growth drivers and clinical visit trends
Q: Chris Schott from JPMorgan asked what is enabling the stronger organic growth target despite unmaterially improved U.S. visit trends, and asked for details on puppy versus older dog visit cohorts.
A: Mike Erickson stated that growth is volume-led and driven by innovations, commercial execution, and pet demographics, noting that growth does not rely on positive visit growth. Andrew Emerson added that the aging pet population continues to support growth while puppy and kitten adoption levels remain more muted.
inVue Dx momentum and long-term targets
Q: Jon Block from Stifel asked whether the strong inVue Dx placements running ahead of near-term expectations alter the 5-year target of 20,000 analyzers.
A: Mike Erickson responded that IDEXX is on track to exceed both the 2026 placement goal of 5,500 and the 5-year goal of 20,000, supported by menu expansions such as fine needle aspirate availability in North America.
Q: Daniel Clark from Leerink Partners asked how inVue revenue per analyzer is trending given it is already in the $3,500 to $5,500 range.
A: Mike Erickson stated that customers comfortably utilize multiple submodalities like cytology and fine needle aspirate, providing long-term upside as availability expands globally.
Q: Daniel Clark from Leerink Partners also asked about the incremental placement opportunity and whether this is a worldwide launch.
A: Mike Erickson confirmed that IDEXX is in full worldwide launch mode for inVue Dx with meaningful headroom to place instruments globally.
Operating margin and CoVet acquisition impacts
Q: Jon Block from Stifel asked if the CoVet acquisition changes 2027 operating margin expansion expectations or if dilution persists into next year.
A: Andrew Emerson explained that approximately 30 basis points of operating margin impact was included for Q3 and Q4 2026, and while managing integration costs and amortization, IDEXX expects to return to long-term annual operating margin expansion of 50 to 100 basis points.
Macro sensitivity and reference lab performance
Q: Erin Wright from Morgan Stanley asked what magnitude of macro sensitivity is baked into guidance and how reference lab double-digit growth is attributed between market share gains and greater customer utilization.
A: Andrew Emerson stated that macroeconomic trends have been relatively consistent with prior guide estimates. Mike Erickson added that reference lab growth is global and driven by network investments, technology, and innovations like Cancer Dx which attracts new customers.
inVue Dx utility and upcoming events
Q: Matt Dellatorre from Goldman Sachs asked what drove strong inVue Dx placements and requested details on the upcoming VMX event for MultiQ Dx.
A: Mike Erickson explained that inVue Dx addresses a core unmet cytology need by eliminating manual glass slides, and noted that further details on MultiQ Dx will be shared at the VMX event in Orlando on January 18.
Cancer Dx customer adoption and recurring metrics
Q: Steven Dechert from KeyBanc Capital Markets asked how many clinics ordering Cancer Dx to date are recurring.
A: Mike Erickson stated that over 14,000 customers have ordered and run Cancer Dx, showing great momentum and strong multiplier benefits into broader diagnostics utilization.
Pricing resilience and mast cell tumor feedback
Q: Navann Ty from BNP Paribas asked whether pricing in diagnostics is isolated and expected to remain resilient compared to pharma, and asked for feedback on the mast cell tumor addition.
A: Mike Erickson noted that pricing is focused on value creation and accessibility, citing the $15 Cancer Dx screening price as a driver of volume. He added that customer feedback on the new mast cell tumor panel addition has been very positive.
